Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

The goal of this clinical trial is to test how effective and safe it is to use a combination of two medications, relugolix and enzalutamide, in patients with advanced prostate cancer. We want to see if this combination can help improve the chances of curing the cancer and make the patients live longer without the cancer getting worse. The main questions we want to answer in this study are: * Can using relugolix and enzalutamide together help increase the chances of curing high-risk advanced prostate cancer? * Does this combination treatment help patients live longer without their cancer gett

Trial Details

NCT ID
NCT06130995
Phase
PHASE1
Sponsor
University of Oklahoma
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Relugolix and Enzalutamide
Locations (sample)
  • Oklahoma City, Oklahoma, United States|35.46756,-97.51643

Key Eligibility Criteria

  • Capable of giving signed informed consent;
  • Patients must be ≥18 years of age at the time of signing the informed consent form.
  • Men with a diagnosis of adenocarcinoma of the prostate pathologically proven diagnosis with the following:
  • Locally advanced high-risk prostate defined as i. PSA \>20 ng/mL or ISUP grade 4/5 (Gleason score \>7) or cT2c or ii. Any PSA, any ISUP grade, cT3-…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →